Innovator IBD Breakout Opportunities ETF (NYSEARCA:BOUT – Get Free Report) was the recipient of a large decline in short interest in September. As of September 15th, there was short interest totaling 24 shares, a decline of 89.9% from the August 31st total of 238 shares. Based on an average daily volume of 3,504 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the company’s stock are sold short.
Innovator IBD Breakout Opportunities ETF Stock Up 1.0%
NYSEARCA BOUT traded up $0.45 during trading hours on Thursday, hitting $43.34. 253 shares of the company were exchanged, compared to its average volume of 3,683. The firm has a market cap of $15.17 million, a price-to-earnings ratio of 28.69 and a beta of 1.02. The company has a 50 day moving average of $44.96 and a two-hundred day moving average of $44.61. Innovator IBD Breakout Opportunities ETF has a 52-week low of $35.05 and a 52-week high of $49.41.
Institutional Trading of Innovator IBD Breakout Opportunities ETF
An institutional investor recently raised its position in Innovator IBD Breakout Opportunities ETF stock. Comprehensive Wealth Management LLC increased its position in Innovator IBD Breakout Opportunities ETF (NYSEARCA:BOUT – Free Report) by 122.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 23,403 shares of the company’s stock after purchasing an additional 12,859 shares during the period. Comprehensive Wealth Management LLC owned 6.69% of Innovator IBD Breakout Opportunities ETF worth $850,000 at the end of the most recent quarter.
About Innovator IBD Breakout Opportunities ETF
The Innovator IBD Breakout Opportunities ETF (BOUT) is an exchange-traded fund that is based on the IBD Breakout Stocks Total Return index. The fund tracks an index of US-listed stocks that are likely to breakout, as determined by technical analysis. Holdings are weighted by a mix of fundamental and technical factors BOUT was launched on Sep 13, 2018 and is managed by Innovator.
See Also
- Five stocks we like better than Innovator IBD Breakout Opportunities ETF
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Innovator IBD Breakout Opportunities ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovator IBD Breakout Opportunities ETF and related companies with MarketBeat.com's FREE daily email newsletter.
